VKTX
Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.83
−2.08%Price chart
Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22
Key dataOct 22, 2026
Open$26.34
From 52W high−38.69%
Volume3.52M
Market cap$3.28B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 22, 2026
Open
$26.34
From 52W high
−38.69%
Volume
3.52M
Market cap
$3.28B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
P/E (TTM)
—
RSI (14)
40.1
MomentumView details →
1D Return
−2.08%
YTD Return
−25.77%
SummaryUpdated Jun 1, 2026
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing novel therapies for metabolic and endocrine disorders. Viking has emerged as a significant player in the obesity and metabolic disease treatment space, with multiple drug candidates in various stages of clinical development targeting conditions such as obesity, non-alcoholic steatohepatitis (NASH), and rare metabolic disorders.
Similar companies
Latest newsMore news →
Viking Therapeutics, Inc. announced that it will release its third-quarter 2026 financial results after the market close on October 28, 2026.1d agoViking Therapeutics shares closed at $25.11, down 8.26% from the previous close.6d agoViking Therapeutics shares rose 2.88% from the previous close to settle at $28.53.13d ago